Dr. Dan Guttmann, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1219 Gusdorf Rd, Ste A, Taos, NM 87571 Phone: 505-758-0009 Fax: 505-758-8736 |
Dallas Michael Smuin, MD Orthopaedic Surgery Medicare: Medicare Enrolled Practice Location: 1219 Gusdorf Rd Ste A, Taos, NM 87571 Phone: 575-758-0009 |
Dr. Sean Collins Marvil, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1219 Gusdorf Rd Ste A, Taos, NM 87571 Phone: 703-635-9387 Fax: 575-758-8656 |
Dr. James H Lubowitz, MD Orthopaedic Surgery - Sports Medicine Medicare: Not Enrolled in Medicare Practice Location: 1219 Gusdorf Rd, Ste A, Taos, NM 87571 Phone: 575-758-0009 Fax: 575-758-8736 |
News Archive
The Wall Street Journal: "Indian technology companies are eyeing a coming wave of U.S. spending to digitize health care records. But sensitivity over outsourcing and resistance by American hospitals to sending medical information overseas could thwart efforts to win big contracts." Next year, the U.S. government will dispense billions to "health-care providers who adopt electronic medical records." Doctors are also facing "a federal mandate to upgrade software as the U.S. switches to a new system of insurance billing codes."
Synthego, a leading provider of genome engineering solutions, officially launches today. Synthego's flagship product line, CRISPRevolution, features synthetic guide RNA products designed to accelerate CRISPR/Cas9 and Cpf1 genome engineering research. CRISPRevolution is the first product line to offer economical access to fully synthetic RNA for high fidelity editing and increased precision in genome editing.
Beginning in October, the Graduate School's new Center for Health Sciences will offer a Medical Laboratory Technician, Associate of Applied Science degree and a certificate program in Phlebotomy. The first of many programs to be offered, both curricula provide a combination of coursework and clinical experience with strong emphasis on employability skills such as problem solving, effective communication, professional conduct, and information and technology literacy.
Raloxifene protects postmenopausal women from developing invasive breast cancer whether they are at high or low risk of developing the disease, according to a new study.
› Verified 7 days ago